Table 1.
Baseline and patients’ characteristics.
| All Patients N=140 N (%) |
BRAF-mutated N=82 N (%) |
BRAF-wild type N=58 N (%) |
p* value | |
|---|---|---|---|---|
| Age (years) | 0.23 | |||
| Median, range | 63.0 ± 14.6 | 63.0 ± 14.1 | 66.0 ± 15.0 | |
| Gender | 0.11 | |||
| Male | 74 (52.9) | 48(58.5) | 26(44.8) | |
| Female | 66 (47.1) | 34(41.5) | 32(55.2) | |
| ECOG | 0.17 | |||
| PS 0-1 | 120 (85.7) | 72(83.7) | 51(87.9) | |
| PS 2 | 20 (14.3) | 14(16.3) | 7(12.1) | |
| Number of metastasis during first-line treatment | 0.20 | |||
| 1 | 89 (63.6) | 52(63.4) | 37(63.8) | |
| 2 | 34 (24.3) | 17(20.7) | 17(29.3) | |
| >2 | 17 (12.1) | 13(15.9) | 4(6.9) | |
| Brain metastases | 0.02 | |||
| Yes | 32 (22.9) | 25(30.5) | 7(12.1) | |
| No | 108 (77.1) | 57(69.5) | 51(87.9) | |
| Liver metastases | 0.34 | |||
| Yes | 21 (15.0) | 10(12.2) | 11(19.0) | |
| No | 119 (85.0) | 72(87.8) | 47(81.0) | |
| LDH level | 0.94 | |||
| Normal | 64 (45.7) | 37(45.1) | 27(46.6) | |
| Elevated | 53 (37.9) | 32(39.0) | 21(36.2) | |
| Unknown | 23 (16.4) | 13(15.9) | 10(17.2) | |
| Second‐line therapy received | 0.73 | |||
| Yes | 56 (40.0) | 34 (41.5) | 22 (37.9) | |
| No | 84 (60.0) | 48 (58.5) | 36 (62.1) |